Lack of persistent effects of ketamine in rodent models of depression

Psychopharmacology

Volumn 198, Issue 3, 2008, Pages 421-430

  Popik, Piotr ^a   Kos, Tomasz ^a   Sowa Kućma, Magdalena ^a   Nowak, Gabriel ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressant; Depression; Ketamine; Mouse; NMDA receptor antagonist; Rat

Indexed keywords

APOMORPHINE; BETA ADRENERGIC RECEPTOR; DESIPRAMINE; KETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DEPRESSION; DRUG EFFECT; EXPERIMENTAL ANIMAL; FORCED SWIMMING TEST; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SINGLE DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; APOMORPHINE; CEREBRAL CORTEX; DEPRESSION; DESIPRAMINE; DOPAMINE AGONISTS; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; KETAMINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; SWIMMING;

EID: 44249084403     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1158-z     Document Type: Article

References (52)

1. Ainsworth K, Smith SE, Sharp T (1998) Repeated administration of fluoxetine, desipramine and tranylcypromine increases dopamine D2-like but not D1-like receptor function in the rat. J Psychopharmacol 12:252-257
2. Belozertseva I, Kos T, Popik P, Danysz W, Bespalov AY (2007) Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 17:172-179
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiat 47:351-354
4. Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147-160
5. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147
6. Chaturvedi HK, Chandra D, Bapna JS (1999) Effect of NMDA antagonists in forced swimming test and its modification by antidepressants. Indian J Pharmacol 31:104-109
7. Check E (2006) Depression: comfortably numb. Nature 443:629-631
8. Correll GE, Futter GE (2006) Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 7:92-95
9. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11:58-65
10. Cryan JF, Page ME, Lucki I (2005a) Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 182:335-344
11. Cryan JF, Valentino RJ, Lucki I (2005b) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29:547-569
12. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121:66-72
13. Detke MJ, Johnson J, Lucki I (1997) Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5:107-112
14. Frazer A (1997) Pharmacology of antidepressants. J Clin Psychopharmacol 17(Suppl 1):2S-18S
15. Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32:140-144
16. Goforth HW, Holsinger T (2007) Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. JECT 23:23-25
17. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268-283
18. Hayase T, Yamamoto Y, Yamamoto K (2006) Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci 7:1-10
19. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7:837-844
20. Kos T, Legutko B, Danysz W, Samoriski G, Popik P (2006a) Enhancement of antidepressant-like effects but not BDNF mRNA expression by the novel NMDA receptor antagonist neramexane in mice. J Pharmacol Exp Ther 318:1128-1136
21. Kos T, Popik P, Pietraszek M, Schafer D, Danysz W, Dravolina O, Blokhina EA, Galankin T, Bespalov AY (2006b) Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol 16:297-310
22. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
23. Lannes B, Micheletti G, Warter JM, Kempf E, Di Scala G (1991) Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci Lett 128:177-181
24. Layer RT, Popik P, Olds T, Skolnick P (1995) Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 52:621-627
25. Liebrenz M, Stohler R, Borgeat A (2007) Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry i:1-4
26. Maeng S, Zarate CA Jr., Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352
27. Mantovani M, Pertile R, Calixto JB, Santos AR, Rodrigues AL (2003) Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci Lett 343:1-4
28. Martin D, Lodge D (1985) Ketamine acts as a non-competitive N-methyl-d-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology 24:999-1003
29. Muscat R, Papp M, Willner P (1992) Antidepressant-like effects of dopamine agonists in animal model of depression. Biol Psychiatry 31:937-946
30. Ostroff R, Gonzales M, Sanacora G (2005) Antidepressant effect of ketamine during ECT. Am J Psychiatry 162:1385-1386
31. Papp M, Moryl E (1993) Similar effect of chronic treatment with imipramine and the NMDA antagonists CGP 37849 and MK-801 in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol 3:348-349
32. Paul IA, Trullas R, Skolnick P, Nowak G (1992) Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology 106:285-287
33. Popik P, Kostakis E, Krawczyk M, Nowak G, Szewczyk B, Krieter P, Chen Z, Russek SJ, Gibbs TT, Farb DH, Skolnick P, Lippa AS, Basile A (2006a) The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl] (pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha-1 subunit-containing GABAA receptors. J Pharmacol Exp Ther 319:1244-1252
34. Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa AS, Basile A (2006b) Pharmacological profile of the "triple" monoamine uptake inhibitor, DOV 102,677. Cell Mol Neurobiol 26:855-871
35. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732
36. Riedlinger TJ, Riedlinger JE (1994) Psychedelic and entactogenic drugs in the treatment of depression. J Psychoactive Drugs 26:41-55
37. Rosa AO, Lin J, Calixto JB, Santos AR, Rodrigues AL (2003) Involvement of NMDA receptors and l-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 144:87-93
38. Sitland-Marken PA, Wells BG, Froemming JH, Chu CC, Brown CS (1990) Psychiatric applications of bromocriptine therapy. J Clin Psychiatry 51:68-82
39. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25
40. Spyraki C, Fibiger HC (1981) Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74:195-206
41. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370
42. Trujillo KA, Zamora JJ, Warmoth KP (2008) Increased response to ketamine following treatment at long intervals: implications for intermittent use. Biol Psychiatry 63:178-183
43. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1-10
44. Verma A, Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379
45. Vetulani J, Sulser F (1975) Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257:495-496
46. Vetulani J, Nalepa I, Popik P (1991) Strain differences in changes in some parameters of cerebral cortical adrenergic system following chronic imipramine administration to rats. Pol J Pharmacol Pharm 43:187-195
47. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on striatal dopamine: a [C-11]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43
48. Wesolowska A, Tatarczynska E, Nikiforuk A, Chojnacka-Wojcik E (2007) Enhancement of the anti-immobility action of antidepressants by a selective 5-HT(7) receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 555:43-47
49. Willner P (1991) Animal models of depression. In: Willner P (ed) Behavioural models in psychophramacology: theoretical, industrial and clinical perspectives. Cambridge University Press, Cambridge, pp 91-124
50. Willner P, Muscat R, Papp M (1992) Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16:525-534
51. Yilmaz A, Schulz D, Aksoy A, Canbeyli R (2002) Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71:341-344
52. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864